Now live: Pro — the full 13F research suite for serious investorsSee pricing →
JOHNSON & JOHNSON (JNJ)

Q4 2024 · 13F-HR

JOHNSON & JOHNSON (JNJ)holdings as filed

Filed 2025-02-13 · accession 0000904454-25-000124

$386.1M
Reported value
20
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74366E102PTGXProtagonist Therapeutics Inc.$94.5M24.5%2,449,183CommonSHARED
126638105CVRXCVRx, Inc.$52.0M13.5%4,103,430CommonSHARED
75383L102RAPPRapport Therapeutics, Inc.$44.3M11.5%2,498,051CommonSHARED
G59665102MGTXMeiraGTx Holdings plc$40.4M10.5%6,641,064CommonSHARED
21217B100CTNMContineum Therapeutics Inc.$29.0M7.51%1,979,173CommonSHARED
74276L105PRCTProcept BioRobotics Corporation$28.8M7.46%357,939CommonSHARED
52490G102LEGNLegend Biotech Corporation$26.5M6.86%814,586CommonSHARED
640979100NMRANeumora Therapeutics, Inc.$19.6M5.08%1,849,445CommonSHARED
98401F105XNCRXencor, Inc.$17.2M4.45%748,062CommonSHARED
63009J107NBTXNanobiotix S.A.$16.1M4.18%5,623,816CommonSHARED
31189P102FATEFate Therapeutics, Inc.$5.6M1.44%3,379,064CommonSHARED
04280A100ARWRArrowhead Pharmaceuticals, Inc.$4.7M1.21%247,598CommonSHARED
75120L100Rallybio Corporation$3.5M0.90%3,636,363CommonSHARED
929033108Vor Biopharma, Inc.$1.2M0.31%1,074,658CommonSHARED
M70700105NNOXNano-X Imaging Ltd.$1.1M0.30%158,852CommonSHARED
34385P108LABStandard BioTools Inc$545,9420.14%311,967CommonSHARED
55083R104Lyell Immunopharma Inc.$526,9230.14%823,317CommonSHARED
007002108TORCEURAdicet Bio, Inc.$350,6220.09%364,472CommonSHARED
09090D103BiomX Inc.$70,7220.02%96,866CommonSHARED
81727U105SENS1GBPSenseonics Holdings, Inc.$28,5890.01%54,621CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.